| Type | Value |
|---|---|
| cik | 0001823878 |
| ticker | MYPS |
Discretionary BUY minus SELL in USD over rolling windows. Excludes compensation flow.
| Date | Type | Insider | Qty | Price | Signals |
|---|---|---|---|---|---|
| 15 May 2026 | EXERCISE | Agena Joel | 83,334 | 0.00 USD | |
| 15 May 2026 | TAX_WITHHOLDING | Agena Joel | 35,709 | 0.49 USD | |
| 15 May 2026 | EXERCISE | Agena Joel | 83,334 | 0.00 USD | deriv |
| 15 May 2026 | EXERCISE | Peterson Scott Edward | 166,667 | 0.00 USD | |
| 15 May 2026 | TAX_WITHHOLDING | Peterson Scott Edward | 65,584 | 0.49 USD | |
| 18 May 2026 | OTHER | Peterson Scott Edward | 25,271 | 0.00 USD | |
| 18 May 2026 | OTHER | Peterson Scott Edward | 25,271 | 0.00 USD | indirect |
| 18 May 2026 | OTHER | Peterson Scott Edward | 75,812 | 0.00 USD | |
| 18 May 2026 | OTHER | Peterson Scott Edward | 75,812 | 0.00 USD | indirect |
| 15 May 2026 | EXERCISE | Peterson Scott Edward | 166,667 | 0.00 USD | deriv |
| 12 Mar 2026 | GRANT_AWARD | Agena Joel | 125,000 | 0.00 USD | deriv |
| 12 Mar 2026 | OTHER | Agena Joel | 125,000 | 0.00 USD | deriv |
| 12 Mar 2026 | OTHER | Oseland Robert L | 233,333 | 0.00 USD | deriv |
| 12 Mar 2026 | GRANT_AWARD | Oseland Robert L | 233,333 | 0.00 USD | deriv |
| 12 Mar 2026 | GRANT_AWARD | PASCAL ANDREW S | 625,000 | 0.00 USD | deriv |
| 12 Mar 2026 | OTHER | PASCAL ANDREW S | 625,000 | 0.00 USD | deriv |
| 12 Mar 2026 | GRANT_AWARD | Peterson Scott Edward | 250,000 | 0.00 USD | deriv |
| 12 Mar 2026 | OTHER | Peterson Scott Edward | 250,000 | 0.00 USD | deriv |
| 19 Feb 2026 | OTHER | PASCAL ANDREW S | 349,463 | 0.00 USD | |
| 19 Feb 2026 | OTHER | PASCAL ANDREW S | 349,463 | 0.00 USD | indirect |
| 17 Feb 2026 | TAX_WITHHOLDING | PASCAL ANDREW S | 233,871 | 0.49 USD | |
| 17 Feb 2026 | EXERCISE | PASCAL ANDREW S | 208,334 | 0.00 USD | |
| 17 Feb 2026 | EXERCISE | PASCAL ANDREW S | 375,000 | 0.00 USD | |
| 17 Feb 2026 | EXERCISE | PASCAL ANDREW S | 208,334 | 0.00 USD | deriv |
| 17 Feb 2026 | EXERCISE | PASCAL ANDREW S | 375,000 | 0.00 USD | deriv |